Daiichi-Sankyo Co-development Program
Undisclosed
Discovery/Pre-clinicalActive
Key Facts
About Meddenovo Drug Design
Meddenovo Drug Design is a private, pre-clinical stage biotech founded in 2019, specializing in AI-driven cyclic peptide discovery. Its proprietary platform, Mexa, enables the exploration of tens of millions of cyclic peptide candidates per target, integrating generative AI with biophysical validation to deliver high-quality hits rapidly. The company has secured a pre-seed funding round, won the i-Lab 2025 award, and entered a significant co-development partnership with Daiichi-Sankyo, positioning it as an emerging player in the next-generation therapeutics space. Meddenovo employs a platform-plus-partnership business model and is currently pre-revenue.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |